Jennifer West

Love Alabama XC/Track! CAR-T Cell Therapy: Multiple Myeloma

[Jennifer West @JenniferBWest]

@Gini_220 1881

[Jennifer West @JenniferBWest]

@WinshipAtEmory @SagarLonialMD Congrats Dr. Lonial!

[Jennifer West @JenniferBWest]

@SqSehrish 10

[Luciano J Costa @End_myeloma]

“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality - Sedrak - 2026 - Cancer https://t.co/mjjblGpRJQ

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

1/ Thanks @BloodPortfolio for this Point-Counterpoint with @JanakiramMurali. Open access!

How do we decide on cilta-cel vs bsAbs at first relapse in myeloma?

My abbreviated arguments in favor of CAR-T:

1️⃣ CAR-T works very well in CD38-refractory dz (see RW data from @hhashmi87 et al, or as-treated CARTITUDE-4)

2️⃣ Long-term QOL advantage, with ⬇️ long-term time tox with CAR-T vs bsAbs ± dara + continuous IVIG

3️⃣ PFS2 of CAR-T to bsAbs likely will still beat bsAbs to CAR-T sequencing-wise unless bsAbs are time-limited

Of course decision-making needs to be individualized!

[Luciano J Costa @End_myeloma]

Worth the risk of being pedantic... It comes out every major medical meeting. Hazard ratio does not reflect reduction in risk 😉.

[Jennifer West @JenniferBWest]

@Avabelly__ Take the phone away and give back when it is clean. If it doesn’t stay clean, get a flip phone. It works!

[Jennifer West @JenniferBWest]

@Mrymyildiz Wart

[Jennifer West @JenniferBWest]

@Rxhaums @HOPArx @Pharmacy_Times Outstanding!

[Jennifer West @JenniferBWest]

@BhattiLaib9960 Buelah

[Jennifer West @JenniferBWest]

500 UAB CAR-T Patients treated! INCREDIBLE!

[Jennifer West @JenniferBWest]

https://t.co/dtXykv9jsU

[Jennifer West @JenniferBWest]

@End_myeloma Love this! My daughter just graduated from Alabama and is headed to UAB for the dual Masters of Public Health/MBA program! Go Blazers!

[Jennifer West @JenniferBWest]

@IMFjimMYELOMA Not a “new” change.

[DAVA Oncology @DAVAOnc]

JNJ-5322 (BCMAxGPRC5DxCD3 trispecific) in MM: @richaparikh36 (@WinshipAtEmory) shows 100% ORR & ≥CR 88.9% at 18-mo FU; 12-mo PFS 95%; median PFS not reached; prophylactic tocilizumab cuts CRS to 20% with no ICANS; MRD-neg 100% - promising next-gen T-cell engager. #DAVAWhistler

[Jennifer West @JenniferBWest]

Outstanding Multiple Myeloma discussion from Dr. Luciano Costa at the Gulf Coast Oncology Summit! UAB MM Center of Excellence!

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

My thoughts on the selection of the best therapy for a myeloma patient experiencing a first relapse: cilta-cel versus teclistamab plus daratumumab?
#mmsm https://t.co/pFlmtXi9AJ

[Jennifer West @JenniferBWest]

Tec-Dara vs. CAR T-Cell Therapy: Sequencing BCMA-Directed Therapy in Multiple Myeloma | SurvivorNet Connect https://t.co/2MT9TTor87

[Jennifer West @JenniferBWest]

@End_myeloma @ESHaematology @CoMMitTrials Love “treatment cessation!”

[Sara Scott, PharmD, BCOP @saraann9]

See you all at #HOPA26!